A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term ...
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...
58m
Barchart on MSNGilead Sciences - Leader in HIV MedicinesYour FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...
Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...
Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, ...
1d
Queerty on MSNA once-a-year PrEP injection? The results of the first clinical trial look promisingPharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...
Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...
Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...
Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results